Clinical trial
A Multicentre Phase II Prospective Pilot Study of Pharmacokinetic- and TDM-guided Oritavancin Dosing Strategies for the Management of Gram-positive Cardiac Infections (the OSCAR Study)
NCT07550595 is registered in ClinicalTrials.gov with Kirby Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre Phase II Prospective Pilot Study of Pharmacokinetic- and TDM-guided Oritavancin Dosing Strategies for the Management of Gram-positive Cardiac Infections (the OSCAR Study)
- Lead sponsor
- Kirby Institute
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- July 1, 2026
- Completion date
- September 30, 2028
- Enrollment
- 20 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
cardiac device infection, gram-positive bacterial infections, infective endocarditis